National Institute for Health and Clinical Excellence: Difference between revisions
Jump to navigation
Jump to search
imported>Domergue Sumien No edit summary |
imported>Robert Badgett No edit summary |
||
| Line 5: | Line 5: | ||
A structured comparison of [[clinical practice guideline]]s for the [[diabetes mellitus type 2]] found variation in guideline quality with the best guideline being produced by NICE.<ref name="pmid17876024">{{cite journal |author=Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK |title=Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians |journal=Annals of internal medicine |volume=147 |issue=6 |pages=417–22 |year=2007 |month=September |pmid=17876024 |doi= |url= |issn=}}</ref> | A structured comparison of [[clinical practice guideline]]s for the [[diabetes mellitus type 2]] found variation in guideline quality with the best guideline being produced by NICE.<ref name="pmid17876024">{{cite journal |author=Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK |title=Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians |journal=Annals of internal medicine |volume=147 |issue=6 |pages=417–22 |year=2007 |month=September |pmid=17876024 |doi= |url= |issn=}}</ref> | ||
NICE has been criticized in its attempt to balance costs.<ref name="pmid18987366">{{cite journal |author=Steinbrook R |title=Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence |journal=N. Engl. J. Med. |volume=359 |issue=19 |pages=1977–81 |year=2008 |month=November |pmid=18987366 |doi=10.1056/NEJMp0806862 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=18987366&promo=ONFLNS19 |issn=}}</ref><ref name="urlThe Evidence Gap - British Balance Benefit vs. Cost of Latest Drugs - NYTimes.com">{{cite web |url=http://www.nytimes.com/2008/12/03/health/03nice.html |title=The Evidence Gap - British Balance Benefit vs. Cost of Latest Drugs |author=Harris G |authorlink= |coauthors= |date=Dec 3, 2008 |format= |work= |publisher=New York Times |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}</ref> | |||
==References== | ==References== | ||
Revision as of 13:36, 3 December 2008
In the United Kingdom, the National Institute for Health and Clinical Excellence (NICE) is part of the National Health Service. NICE is an "independent organisation responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health."[1]
A structured comparison of clinical practice guidelines for the diabetes mellitus type 2 found variation in guideline quality with the best guideline being produced by NICE.[2]
NICE has been criticized in its attempt to balance costs.[3][4]
References
- ↑ About NICE. National Institute for Health and Clinical Excellence. Retrieved on 2008-08-26.
- ↑ Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK (September 2007). "Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians". Annals of internal medicine 147 (6): 417–22. PMID 17876024. [e]
- ↑ Steinbrook R (November 2008). "Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence". N. Engl. J. Med. 359 (19): 1977–81. DOI:10.1056/NEJMp0806862. PMID 18987366. Research Blogging.
- ↑ Harris G (Dec 3, 2008). The Evidence Gap - British Balance Benefit vs. Cost of Latest Drugs. New York Times.
External links
- http://www.nice.org.uk/ - National Institute for Health and Clinical Excellence website